NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $14.00.
NPCE has been the topic of several research reports. Wells Fargo & Company lowered their price target on NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. Morgan Stanley lowered their price objective on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 target price on shares of NeuroPace in a research report on Wednesday, August 14th.
Check Out Our Latest Research Report on NPCE
Institutional Trading of NeuroPace
NeuroPace Trading Up 2.8 %
Shares of NASDAQ:NPCE opened at $7.43 on Wednesday. The company has a debt-to-equity ratio of 5.97, a quick ratio of 5.47 and a current ratio of 6.37. The stock’s 50-day moving average is $7.40 and its 200-day moving average is $9.68. The company has a market cap of $216.96 million, a P/E ratio of -6.24 and a beta of 1.80. NeuroPace has a 52-week low of $5.75 and a 52-week high of $18.15.
NeuroPace (NASDAQ:NPCE – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. The firm had revenue of $19.26 million for the quarter, compared to analyst estimates of $18.30 million. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The company’s revenue was up 16.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.36) EPS. Equities research analysts predict that NeuroPace will post -1.08 earnings per share for the current year.
NeuroPace Company Profile
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Featured Articles
- Five stocks we like better than NeuroPace
- Insider Trades May Not Tell You What You Think
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- 3 Warren Buffett Stocks to Buy Now
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- The Role Economic Reports Play in a Successful Investment Strategy
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.